Van Paesschen W.
- Country
- Belgium
- Department
- Neurology
Research Overview
- The ENACT Trial: A Randomized, double-blind, placebo-controlled adjunctive treatment trial to evaluate the efficacy and safety of ENX-101 in patients with focal (partial onset) seizures
- A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus
Data & Insights
Has run more than one trial at 2 of 50 partner sites.
Specializations
Epilepsy Management
The investigator specializes in treating complex forms of epilepsy, with particular emphasis on refractory status epilepticus and focal seizures.
- Status Epilepticus Treatment
- Focal Epilepsy Management
- Antiepileptic Therapy
Their research encompasses novel therapeutic approaches for patients with drug-resistant seizure conditions.
Neurological Interventions
The investigator focuses on developing adjunctive treatment strategies for patients with challenging neurological conditions who have not responded adequately to standard therapies.
- Advanced Treatment Protocols
- Therapeutic Drug Combinations
- Refractory Condition Management
Their work includes evaluating innovative therapeutic agents for neurological disorders.
Clinical Assessment
The investigator specializes in evaluating treatment efficacy and safety in patients with severe neurological conditions.
- Treatment Tolerability Assessment
- Safety Profile Analysis
- Long-term Outcome Evaluation
Their expertise extends to comprehensive patient monitoring and therapeutic response assessment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.